Compare TransMedics Group Inc (TMDX) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? TransMedics Group Inc trades at $86.5 (market cap $3.00B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.19. The key difference: TransMedics Group Inc is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| TMDX | YMAG | |
|---|---|---|
Market Cap | $3.00B | — |
Sector | Technology | Income / Options Overlay |
52-Week High | $150.42 | $15.98 |
52-Week Low | $61.99 | $10.76 |
Enterprise Value | $3.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $88.27, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported strong 2025 results with $605M revenue and 31.4% net margin, though 2026 projections show margin compression. Recent news highlights growth initiatives in kidney transplantation and European markets, alongside ongoing legal investigations into fiduciary duties.
The stock offers upside to the $99.57 consensus price target, supported by analyst bullishness (69% buy ratings), but faces risks from margin pressure, legal scrutiny, and earnings misses. Revenue growth remains a key catalyst, though execution risks and investor sentiment headwinds warrant caution.
YMAG trades at $11.26, down 0.18% with a bullish technical signal supported by moving averages. The ETF maintains consistent weekly dividend distributions, though key valuation metrics remain unavailable. Recent trading activity shows moderate volume with price stability around the $11 support level.
The outlook remains cautiously optimistic given the bullish technical setup and income generation, but lack of fundamental data creates uncertainty. Investors face risks from NAV volatility during earnings periods and dependency on option income strategies for distributions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
